BAX and hematologic disorder: Once the ability of the combination of cell-permeable Bak and Bax BH3 peptides was shown to promote death in 78% of Ramos cells and 90% of CCRF-CM cells, better than the chemosensitization efficacy of the hematologic malignancies in the presence of the cell-permeable Bak BH3 peptide and cisplatin, we analyzed whether the combination of these peptides further increased sensitization to chemotherapy in hematologic malignant cells.